Conference item : Abstract
Efficacy and safety of switching from adalimumab to baricitinib: long-term data from phase 3 extension study in patients with rheumatoid arthritis
- Publication status:
- Published
- Peer review status:
- Reviewed (other)
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 224.1KB, Terms of use)
-
- Publisher copy:
- 10.1002/art.40700
Authors
- Publisher:
- Wiley
- Host title:
- Arthritis and Rheumatology
- Journal:
- Arthritis and Rheumatology More from this journal
- Volume:
- 70
- Issue:
- S9
- Pages:
- 886
- Publication date:
- 2018-10-15
- Acceptance date:
- 2018-08-14
- DOI:
- EISSN:
-
2326-5205
- ISSN:
-
2326-5191
- Subtype:
-
Abstract
- Pubs id:
-
pubs:922556
- UUID:
-
uuid:dd548e8d-57c4-407b-bbca-0ea3a1fcb329
- Local pid:
-
pubs:922556
- Source identifiers:
-
922556
- Deposit date:
-
2018-10-01
- ARK identifier:
Terms of use
- Copyright holder:
- American College of Rheumatology
- Copyright date:
- 2018
- Notes:
- © 2018, American College of Rheumatology. This is a conference paper presented at American College of Rheumatology Annual Meeting, October 19 - 24 in Chicago, Illinois. This is the accepted manuscript version of the article. The final version is available online from Wiley at: https://doi.org/10.1002/art.40700
If you are the owner of this record, you can report an update to it here: Report update to this record